Idarubicin (idarubicin): Reviews and patient testimonials
Medication indications
Idarubicin 10 mg/10 ml solution for injection
Cytotoxic and antimitotic agent.
Adults
- For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients.
- For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).
Children
- For first line treatment of acute myeloid leukaemia (AML), in combination with cytarabine, for remission induction.
- For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).
Idarubicin Accord may be used in combination chemotherapy regimens involving other cytotoxic agents.
Idarubicin 20 mg/20 ml solution for injection
Cytotoxic and antimitotic agent.
Adults
- For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients.
- For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).
Children
- For first line treatment of acute myeloid leukaemia (AML), in combination with cytarabine, for remission induction.
- For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).
Idarubicin Accord may be used in combination chemotherapy regimens involving other cytotoxic agents.
Idarubicin 5 mg/5 ml solution for injection
Cytotoxic and antimitotic agent.
Adults
- For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients.
- For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).
Children
- For first line treatment of acute myeloid leukaemia (AML), in combination with cytarabine, for remission induction.
- For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).
Idarubicin Accord may be used in combination chemotherapy regimens involving other cytotoxic agents.
Route of administration: Injectable
Molecule: idarubicin
Patients' opinions on Idarubicin
In brief
General satisfaction level: Be the first to evaluate
Treatment's effectiveness: Be the first to evaluate
Ease of use: Be the first to evaluate
Adherence to prescription: Be the first to evaluate
Detected side effects: Be the first to evaluate
Improvement in the quality of life: Be the first to evaluate
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.